key: cord-0743368-qqnixpuz
authors: Sumpaico-Tanchanco, L. B. C.; Sy, J. C. Y.; Dy, A. B. C.; Levantino, M.; Amit, A. M. L.; Wong, J.; Angeles, K.; Vergara, J. P. C.
title: The prevalence of SARS-CoV-2 antibodies within the community of a private tertiary university in the Philippines: a serial cross sectional study
date: 2022-04-27
journal: nan
DOI: 10.1101/2022.04.25.22274280
sha: 74ce9fcebc2395f007a0ef0d9d11859fc7e31c39
doc_id: 743368
cord_uid: qqnixpuz

The antibody testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was used to detect the presence of antibodies in a private university setting. This serial cross-sectional study determined the seroprevalence of SARS-CoV-2 antibodies using qualitative and quantitative tests. Between June 2021 to December 2021, samples from 1,318 participants were tested, showing 47.80% of the study population yielding IgG antibodies to SARS-CoV-2 virus. A general increase in seroprevalence was observed from June to December 2021. However, a decreasing trend in IgG reactivity was found in vaccinated individuals over time. IgG antibody formation was observed across all brands of vaccines.

tests, involved more than 150,000 individuals, and the second phase, which utilizes the finger prick antibody 51 tests, is currently ongoing (1) . A multi-country study involving the seroprevalence of COVID-19 antibodies, 52 called Solidarity II, is also being conducted by the World Health Organization (WHO) in order to fill in the 53 knowledge gaps of the global epidemiology of Antibody testing is instrumental in generating epidemiological information necessary for the control 55 of infectious diseases, including COVID-19. The surveillance of COVID-19 is necessary in order to 56 determine disease burden in the population and to detect vulnerable groups who are at high risk. 57

Determining the prevalence of COVID-19 is important in understanding the widespread outbreak of the 58 disease, transmission of the virus, and the immunity status of the population. In order to implement proper 59 strategies to eradicate COVID-19, it is crucial to identify the number of people previously and currently 60 infected with the virus, and who are most at risk. 61

Widespread COVID-19 testing can help the country determine the true state of infection of the 62 community and identify hotspots and high-risk populations. However, large-scale molecular testing, such 63 as RT-PCR detection, is not easily achievable due to limitations in testing kits and expenses. At the time of 64 this study, there were initially 219 laboratories that were accredited by the Department of Health (DOH) to 65 conduct COVID-19 RT-PCR testing, which increased to 280 laboratories in October 2021 (10). There was 66 an average testing of about 50,000 to 58,000 daily, and positivity rates ranged from 10.6% to 28.1% from 67

June to October 2021. 68 Antibody testing is a reliable diagnostic alternative that can be used (11). It is a preferable option 69 in testing at a large-scale, especially if the tests used exhibit quality performance. It involves a simple lateral 70 flow test that only requires a minute amount of blood with no lab processing. This assay detects antibody 71 responses that can be used to diagnose acute infection. It can be used to detect binding antibodies and 72 identify recovered cases through remaining IgG antibodies (12). SARS-CoV2 infected patients mostly 73 exhibit an antibody response 10-15 days after infection, and there is a sequential or simultaneous 74 seroconversion for immunoglobulin G (IgG) and immunoglobulin M (IgM) (13). Quantitative antibody tests 75 may determine antibody titers, enable longitudinal monitoring of antibody levels in patients, and potentially 76 monitor antibody response to vaccines. 77 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 27, 2022. ;

The primary objective of this study is to determine the seroprevalence of antibody titers in 78 employees in an tertiary academic university across a 6 month period. The secondary objective is to 79 determine the association between sociodemographic characteristics, familial history, vaccine brand, 80 The computed sample size was at least 400 to ensure that the 95% CI will be an interval with length 95 less than 0.10 (point estimate ±< 0.05 margin of error) (14,15). However, a total of 500 participants was 96 targeted for recruitment to account for potential dropouts. 97

The study was reviewed and approved by the Institutional Review Board (IRB) from the School of 98

Medicine and Public Health Panel of the AdMU Research Ethics Committee. Informed consent was secured 99 prior to inclusion to the study through the digital data collection tool used in the study. 100

101 BluEHR (Tantum Quantum Headquarters, Inc), a cloud-based electronic medical record (EMR) 102 was used as the main data collection tool for this project. 103 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 27, 2022. ; https://doi.org/10.1101/2022.04.25.22274280 doi: medRxiv preprint Sample collection and antibody testing 104 A medical professional (medical technologist or physician) collected blood samples from the 105 participants. The Roche SARS-CoV-2 Rapid Antibody Kit was used for the qualitative antibody testing. It 106 has a specificity of 100% and sensitivity of 92%. Twenty (20) μl of blood was obtained through finger 107 pricking. The collected blood was added to the test device, followed by 90 μl (approximately 3 drops) of 108 buffer. The test was incubated for 10-15 mins before interpretation. Participants with reactive IgM results 109 were referred to the university physician as it was beyond the scope of this study to do confirmatory rt-PCR 110 testing. <"-@#$9,&>#7$*,$50CE2B$%#9)@,9$<#>#$-+,#>D>#,#7$*9$=&@@&<9F$.*@)#9$GHBI$JKAL$*>#$'&+9-7#>#7$+&+0>#*',-.#M$ 115 *+7$.*@)#9$NHBI$JKAL$*>#$'&+9-7#>#7$>#*',-.#B$!"#$&),9&)>'#7$@*6&>*,&>8$-9$@-'#+9#7$=&>$&D#>*,-&+$68$,"#$ 116 O#D*>,A#+,$&=$P#*@,"$*+7$-9$*@9&$>#:-9,#>#7$*,$,"#$Q*,-&+*@$R>-.*'8$2&AA-99-&+B$ 117

118 Seroprevalence was defined as the proportion of participants with a reactive IgG result in the 119 qualitative rapid antibody test (16). The data was analyzed using SPSS software (version 28.0.1.0) and 120 Google Sheets. 121

Univariate analysis was conducted to provide the descriptive statistics of the study population. 122

Frequency distributions were made for categorical variables, and the mean, standard deviations, median, 123 and quartiles were obtained for continuous variables (i.e. age and quantitative count). 124

Bivariate analyses were performed using chi-square tests, independent t-tests, and a one-way 125 analysis of variance (ANOVA). This was used to look at the relationship between categorical variables, in 126 addition to the logistic regression. Binomial logistic regression modeling was also performed as a 127 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 27, 2022. ; https://doi.org/10.1101/2022.04.25.22274280 doi: medRxiv preprint multivariate analysis, to obtain odds ratios and determine the relationship between the dependent variable 128 with one or more independent variables. Results were considered statistically significant if p-values were 129 less than 0.05. 130

The following nonbinary variables were collapsed into dichotomous variables to fulfill the 131 assumptions for the chi-square tests (to compare the two groups with respect to the outcome variables) 132 and were also used for the multivariate tests: Other variables were already dichotomous (i.e. sex, comorbidities). One-way ANOVA was used to 144 analyze a relationship between the quantitative count and vaccine brands. Tukey's HSD was used as a 145 post hoc test. 146

In order to compare the results of the qualitative and quantitative antibody tests, a receiver 147 operating characteristic (ROC) analysis was performed (17,18). The most plausible U/ml cutoff for the 148 qualitative test kit was estimated by considering each measurement as a candidate cutoff point and 149 computing the resulting accuracies. In this specific analysis, accuracy is defined as the percentage of 150 correctly classified data points over N=291, where "correctly classified" is determined by using the results 151 obtained from the qualitative test as ground truth. 152 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) Among the participants, 50.8% were males and 49.2% were females. The study population ages 158 ranged from 20 to 87, with a median age of 38 years (SD±13.1). Majority of them were college graduates 159 or with postgraduate degrees (87.5%). Work arrangements of the participants also varied in that 33.1% 160 worked remotely, while 55.5% had onsite work. Almost half (49.5%) of participants reported having at least 161 one comorbidity, with hypertension being the most common (Table 2) . 162 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Excluding participants who were previously infected, the total antibody titers ranged from 0.4 U/mL 181 to >25,000 U/mL in the quantitative test (n=409). The mean was 3,099.56 U/mL across all brands, and the 182 descriptives are further summarized in Table 3 . 183 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 27, 2022. ; https://doi.org/10.1101/2022.04.25.22274280 doi: medRxiv preprint

The results of the qualitative antibody test were correlated with the quantitative test in order to 186 identify a cutoff value at which participants received a reactive IgG result. Fig 3 displays the resulting  187 accuracies against the candidate cutoff points and it reveals that a threshold of 169.5 U/ml yielded 188 maximum accuracy (89.35%). This means that a positive result from the qualitative test occurs when at 189 least 169.5 U/ml is detected from the specimen (note that the candidate value before this cutoff is 152, so 190 alternatively, the condition can be stated as > 152). . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 27, 2022. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. We observed a seroprevalence rate that ranged from 28.76% to 65.15% among members of the 229 community, from June to December 2021. There was no significant difference in seroprevalence by gender 230 and age in the study population. Seropositivity in the analysis was mainly due to the antibody response 231 there was an increase in seropositivity rates after the first dose (88%), and an even higher seropositivity 238 rate after the second dose (99%) (24). 239

Although vaccination rates were high across the study population, a decreasing trend in the 240 seroprevalence was found over time after vaccination. After the development of an antibody response to 241 the S protein of the virus, a decline in antibody levels has been observed after 3 months and after 6 months 242 of the second dose (20,24,25). This may explain the decline in seroprevalence found in our results over 243 time. There was a decline in seropositivity rates from vaccination. This decrease of antibodies over time 244 supports the need for booster shots that was recommended by the Department of Health. This also supports 245 the continuous use of health precautions like use of masks, frequent handwashing and social distancing. 246 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 27, 2022. ; https://doi.org/10.1101/2022.04.25.22274280 doi: medRxiv preprint Among the risk factors included in the study, only obesity and smoking status were significantly 247 associated with IgG serology. Similar to this, a seroprevalence study in Switzerland (5) and Russia (26) 248 showed that current smokers were less likely to have reactive serology results compared to non-smokers, 249 though these studies only focused on seropositivity after infection. Chronic health conditions were also not 250 significantly associated with serology results in the Switzerland population (5). However, contrary to our 251 results, this study also reported that obese women had higher odds of receiving reactive serology results 252 compared to non-obese women, but there were no differences observed in male participants. Because of the decreasing trend of antibody levels, it is recommended that vaccination status of 283 individuals need to be monitored by university officials and guidelines for booster doses are followed. Since 284 all the vaccines examined showed antibody positivity, these brands can be considered when available. 285

Antibody testing is not recommended to monitor the status of current infection in the community. It can be 286 used, however, for epidemiological surveillance purposes to assess herd immunity. 287

It is recommended that public health safety measures like wearing of masks, frequent hand 288 washing, social distancing be continued. Contact tracing and monitoring especially in in-campus dormitories 289 should be enforced. While vaccination is one of several methods that should be done to ensure safety 290 against COVID-19, it is recommended that a surveillance system, such as waste water surveillance and 291 air sampling, be implemented as environmental measures to monitor the spread of the virus. An effective 292 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) 

SARS-CoV-2 lateral flow assays 308 for possible use in national covid-19 seroprevalence surveys (React 2): diagnostic accuracy study

COVID-19 Serosurveillance May Facilitate Return-to-Work 311

Centers for Disease Control 313 and Prevention

Seroprevalence of immunoglobulin M and G 316 antibodies against SARS-CoV-2 in China

Seroprevalence of anti-318 SARS-CoV-2 IgG antibodies in

Seroprevalence 321 of SARS-CoV-2 in Guilan Province

CoV-2 in Hong Kong and in residents evacuated from Hubei province, China: a multicohort study. 324 Lancet Microbe

Seroprevalence of Antibodies 326 to SARS-CoV-2 in 10 Sites in the United States

Seroprevalence of SARS-CoV-2 IgM and IgG antibodies in an asymptomatic population in Sergipe

Rev Panam Salud Pública

COVID-19 Case Tracker | Department of Health website

Serology testing 334 in the COVID-19 pandemic response

Antibody testing for 336 COVID-19: A report from the National COVID Scientific Advisory Panel

Value and Validity of Coronavirus Antibody Testing. Pain Physician

Basic Methods for Sensitivity Analysis of Biases

Estimating Prevalence Using an Imperfect Test

Seroprevalence 345 Study and Cross-Sectional Survey on COVID-19 for a Plan to Reopen the University of Alicante 346 (Spain)

Using and Interpreting Diagnostic Tests with Quantitative Results

On determining the most appropriate test 352 cut-off value: the case of tests with continuous results

Dynamics of antibody response 356 to BNT162b2 vaccine after six months: a longitudinal prospective study. Lancet Reg Health -Eur

mRNA vaccination boosts 359 cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection

COVID-19 362 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants

Differential Antibody Response 365 to mRNA COVID-19 Vaccines in Healthy Subjects

Dynamics of antibody 369 response to CoronaVac vaccine

Waning antibody levels after 372 COVID-19 vaccination with mRNA Comirnaty and inactivated CoronaVac vaccines in blood donors

Seroprevalence of SARS-CoV-2 antibodies in Saint Petersburg, Russia: a population-based study

Seroprevalence 378 of COVID-19 infection in the Emirate of Abu Dhabi, United Arab Emirates: a population-based cross-379 sectional study

Population-based seroprevalence surveys of anti-SARS-CoV-2 381 antibody: An up-to-date review

Seroprevalence of 383 SARS-CoV-2 antibodies and knowledge, attitude and practice toward COVID-19 in the

A population-based study

Evaluation of COVID-19 Testing 386 Strategies for Repopulating College and University Campuses: A Decision Tree Analysis

University population-389 based prospective cohort study of SARS-CoV-2 infection and immunity (SARSSURV-ULiège): a 390 study protocol

Modeling for COVID-392 19 college reopening decisions: Cornell, a case study

How to Safely Reopen Colleges and Universities 395 During COVID-19: Experiences From Taiwan